TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22928803
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin Type-A (BoNT-A) injection
Study: 21342644
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed concurrent chemoradiotherapy (Paclitaxel liposme 135 mg/m²-175 mg/m², d1 and cisplatin 70 mg/m²-80 mg/m², d2, 3 weeks repeat)
Study: 21342644
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy (4-6 cycles of chemotherapy followed by one cycle of radiotherapy)
Study: 21342644
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed concurrent chemoradiotherapy
Study: 21342644
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy
Study: 19688338
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily (n = 230)
Study: 19688338
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n = 232)
Study: 19039821
Drug: Modafinil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (300 mg)
Study: 3516092
Drug: tibalosine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibalosine 150 mg daily
Study: 3516092
Drug: tibalosine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibalosine plus atenolol 100 mg
Study: 3516092
Drug: tibalosine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibalosine plus chlorthalidone 50 mg
Study: 31053348
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered before skin incision
Study: 31053348
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered after cutting the umbilical cord
Study: 25838311
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite (NaNO2) at 50 μg/kg/min
Study: 25838311
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium nitrite (NaNO2) at 10 μg/kg/min
Study: 23785676
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy in 57 allergic patients (70.3%)
Study: 23785676
Drug: Intranasal glucocorticosteroids
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glucocorticosteroids in 47 patients with rhinitis medicamentosa (37.9%)
Study: 20979591
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.i.d
Study: 15536601
Drug: No pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacologic treatment
Study: 11559654
Drug: olsalazine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: olsalazine 2.0 g daily for 52 weeks
Study: 9211442
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment for 6 weeks
Study: 2527533
Drug: Cilazapril (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (0.5 to 5 mg dose range)
Study: 21344327
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (amoxicillin and metronidazole) in combination with non-surgical subgingival debridement
Study: 16403695
Drug: 10-session cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-session cognitive behaviour therapy-based group intervention
Study: 12808136
Drug: Insulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (1.5 milliunits/kg of fat‐free mass per min)
Study: 12808136
Drug: Insulin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (low to high levels)
Study: 10702462
Drug: Remifentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (50 microg/mL) by syringe from an infusion pump
Study: 10702462
Drug: Remifentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 20 microg/mL through a minidrip set
Study: 9112968
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of botulinum toxin type A (BtA)
Study: 7968331
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL 2% lidocaine intrathecally (Group A)
Study: 7968331
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL 2% lidocaine epidurally (Group B)
Study: 2702851
Drug: bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (600 mg/day)
Study: 29395407
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy session after wound care in addition to standard care
Study: 29395407
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy for children older than 5 years
Study: 9640121
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target concentration of 6 micrograms.ml‐1
Study: 31664751
Drug: 3% TA
Normalized name: Doak 3% Tar Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% TA combination serum (3% TA, 4% galactomyces ferment filtrate, 2% niacinamide, and 4% alpha arbutin)
Study: 31664751
Drug: 2% TA
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% TA combination serum
Study: 22257645
Drug: DHEA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA + COC (oral micronized DHEA 50 mg + 20 µg ethinyl estradiol/0.1 mg levonorgestrel combined oral contraceptive pill daily; n = 43)
Study: 17448045
Drug: GAC brackets
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GAC brackets (G)
Study: 14752639
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (ABP)
Study: 12002922
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg IV
Study: 15315625
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg IV
Study: 9653594
Drug: Glimepiride plus
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride plus insulin (GI)
Study: 9653594
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus insulin (PI)
Study: 2708607
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment combined with response prevention of vomiting
Study: 29057266
Drug: Tapered double-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered double-lead threads single implants placed at the time of tooth extraction (TG)
Study: 29057266
Drug: Tapered double-lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapered double-lead threads single implants placed 3 months after extraction (CG)
Study: 23378222
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to sexual visual cues ON dopamine medication
Study: 23378222
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to sexual visual cues OFF dopamine medication
Study: 19477891
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg daily for 14 days)
Study: 11440560
Drug: Placebo antitussive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo antitussive syrup (60 ml)
Study: 6129752
Drug: beta-receptor blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-receptor blockers (talinolol and propranolol)
Study: 28688338
Drug: Pregnenolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (50 mg/day)
Study: 23217477
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Study: 23217477
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anaesthesia (1.5 ml of 0.75% hyperbaric bupivacaine)
Study: 20382445
Drug: Intravenous 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.15 μg/kg sufentanil, followed by 0.075 μg/kg every 3 minutes
Study: 20382445
Drug: Intravenous 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.15 mg/kg morphine, followed by 0.075 mg/kg
Study: 12709777
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg LY354740
Study: 12709777
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LY354740
Study: 10498345
Drug: 200 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU/day of nasal spray of salmon calcitonin
Study: 1403034
Drug: Aminoglutethimide (AG)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (AG) 250 mg four times per day and hydrocortisone 20 mg twice per day
Study: 4002791
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg muzolimine after a standardized breakfast with 1760 mg aluminium hydroxide administered 10 min before breakfast
Study: 4002791
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg muzolimine after a standardized breakfast without aluminium hydroxide
Study: 27852385
Drug: Jinghuaweikang capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghuaweikang capsules + furazolidone-based triple therapy (group A1)
Study: 27852385
Drug: Jinghuaweikang capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghuaweikang capsules + furazolidone-based quadruple therapy (group A2)
Study: 27852385
Drug: Bismuth potassium
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate + furazolidone-based triple therapy (group B1)
Study: 27852385
Drug: Bismuth potassium
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate + furazolidone-based quadruple therapy (group B2)
Study: 23173249
Drug: qi supplementing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: qi supplementing, collateral dredging, detoxifying, and turbidity descending recipe (QSCDDTDR) combined with basic methods of Western medicine (WM)
Study: 20351374
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment applied at LU6, LI4, ST36 and ST6 for 30 min after exercise
Study: 20351374
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (rest without acupuncture)
Study: 7480918
Drug: Oral levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levamisole
Study: 2340610
Drug: Midazolam (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.07 mg.kg‐1), fentanyl (1 microgram.kg‐1), propofol (2 mg.kg‐1), succinylcholine (1 mg.kg‐1), anaesthesia maintained with propofol (6 mg.kg‐1.hr‐1), N2O (67 per cent), O2 (33 per cent)
Study: 2340610
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg.kg‐1), anaesthesia maintained with N2O (67 per cent), O2 (33 per cent), enflurane (0.5 per cent inspired concentration)
Study: 6767648
Drug: Butalamine hydrochloride
Normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butalamine hydrochloride (Adrevil forte) 3 x 2 tablets daily
Study: 23422925
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg daily for 13 days
Study: 23422925
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg daily for 13 days in MDR1 3435 TT individuals
Study: 23422925
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg daily for 13 days in MDR1 3435 CT individuals
Study: 22027785
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg/day
Study: 15308911
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous morphine infusion (20 mg/day)
Study: 11554438
Drug: Theophylline (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (375 mg)
Study: 11554438
Drug: Theophylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (500 mg)
Study: 3147048
Drug: Theophylline (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (all doses)
Study: 9755997
Drug: Omeprazole (PPI)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (PPI) administered through a jejunal tube after PPPD
Study: 9755997
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution administered through a jejunal tube (Control group)
Study: 3280316
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone 5 mg kg‐1 with Tween 80 (A)
Study: 3280316
Drug: Intravenous amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amiodarone 5 mg kg‐1 without Tween 80 (N)
Study: 29797913
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with western medication (dehydration and nutritional nerve treatment), treatment given once daily for 6 times per course, with 4 courses total.
Study: 29797913
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (dehydration and nutritional nerve treatment) alone.
Study: 22917636
Drug: Arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2 (bisacodyl the day before and 2-L polyethylene glycol with citrates and simethicone on the day of colonoscopy)
Study: 22917636
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (split-dose of 4-L polyethylene glycol)
Study: 22917636
Drug: Arm 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 (bisacodyl and 2-L polyethylene glycol with citrates and simethicone the day before)
Study: 18403671
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg of salbutamol aerosol with a spacer device for bronchodilation
Study: 15684169
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg, 3 times a day for 10 days
Study: 12604505
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion (60 micromol x kg(‐1) x min(‐1))
Study: 12604505
Drug: Isomolar sodium
Normalized name: Watersoluble, nephrotropic, high osmolar X-ray contrast media
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomolar sodium bicarbonate infusion
Study: 10535525
Drug: Desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFO) infusion
Study: 10535525
Drug: No DFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DFO infusion
Study: 1768540
Drug: Paravertebral bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral bupivacaine (PVB) infusion
Study: 1768540
Drug: Paravertebral saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral saline (PVS) infusion
Study: 462160
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum intrapleurally as adjuvant therapy
Study: 30360637
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure (500 μg/cm3)
Study: 23932139
Drug: Long-chain inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-chain inulin (20g/L) added to low-fat yogurt
Study: 17403972
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) guided self-care
Study: 30935010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of white bread and sour milk cheese (food)
Study: 25530603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed partial treatment of school fees only)
Study: 23400614
Drug: School-Based Asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-Based Asthma Therapy (SBAT) program - administration of 1 dose of preventive asthma medication at school by the school nurse each school day.
Study: 19108788
Drug: Azithromycin 1%
Normalized name: AZITHROMYCIN 1% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1% ophthalmic solution
Study: 19108788
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Azithromycin and Moxifloxacin)
Study: 17414766
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of contrast material (350 mg of Iodine per milliliter)
Study: 17414766
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of contrast material (350 mg of Iodine per milliliter)
Study: 17414766
Drug: Contrast volume
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast volume > 0.9 mL/kg body weight
Study: 15355127
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 500 mg twice daily
Study: 11436969
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray and eye drops
Study: 9752515
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy followed by locoregional treatment (Group B, n = 134)
Study: 7826821
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate 600 mg
Study: 3288172
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with Biofeedback (BFB) and FES
Study: 29992264
Drug: Standardized classification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized classification and framework for reporting medication non-adherence
Study: 23086792
Drug: Transendocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injection of bone marrow-derived mononuclear cells (BMC)
Study: 19175512
Drug: Insuflon (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insuflon (subcutaneous injection port)
Study: 15860712
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g PUFA daily
Study: 9661647
Drug: iv arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv arginine infusion (30 g) over 30 min
Study: 9661647
Drug: oral L-dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral L-dopa (500 mg)
Study: 8136670
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of diuretics
Study: 8136670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued diuretic use)
Study: 31254130
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A at the recommended dietary allowance (400 μg retinol activity equivalents/day)
Study: 31254130
Drug: Maize enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize enhanced with β-carotene (2.86 mg/day)
Study: 10743869
Drug: Group no.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group no. 1 (substituted toothbrush monthly)
Study: 3905054
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg of aspirin daily for 12 weeks
Study: 3905054
Drug: heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin therapy
Study: 3905054
Drug: nitrates, beta-blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrates, beta-blockers, calcium blockers, fibrinolytic therapy, and coronary angioplasty
Study: 27151322
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (30-g brown milled flaxseed daily)
Study: 24075240
Drug: Tears Again™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tears Again™ liposome spray
Study: 24075240
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hypromellose drops and Tears Again™ liposome spray
Study: 15920184
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 0.25 mg/kg (D 0.25)
Study: 15920184
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 0.5 mg/kg (D 0.5)